Redfund Supports Alzheimer Defense
RxMM Healthcare Subsidiary Direct Investment
Redfund Capital Corp. (
CSE: LOAN,
OTCQB: PNNRF,
Forum) has announced its financing of RxMM Health Capital Inc.’s subsidiary RxMM Healthcare Inc. (“RxMM).
RxMM Health Capital Inc. is a medical cannabis company incorporated in Vancouver, British Columbia. RxMM comprises of a group of six subsidiary companies that are involved in the cultivation, extraction and manufacturing of pharmaceutical grade cannabis for OTC medical and wellness products. The Company is planning to have over 4 million sq. of pharma-grade cannabis under cultivation by mid-2022.
RxMM’s subsidiary RxMM Healthcare Inc. is in the process of launching Alzheimers Defense (“AD”) which is a proprietary, CBD infused “all natural” nutraceutical product. AD’s claims are underpinned by two scientific research studies, funded by the National Institutes of Health and conducted at the University of California, Irvine, Institute for Memory Impairments and Neurological Disorders (UCI MIND) and the University of Kentucky. Both these studies support the AD’s efficacy claims. Currently, there is no other preventative Dementia/ Alzheimer product on the market with evidence to support product efficacy claims. (
www.rxmmhealthcare.com;
https://www.rxmmhealthcapital.com)
RxMM Healthcare products to be marketed consist of Alzheimer’s Defense daily tablets, Alzheimer’s Defense PLUS+ CBD daily gel caps, FDA approved NeuroNasal Strips and CBD PLUS+ anti-oxidant topical patches to support overall antioxidant and anti-inflammatory wellness for up to 72-hours.
The Investment
Redfund and RxMM signed a 2-year term convertible secured promissory note on October 5
th, 2018 for $500,000 at an annual interest rate of 14%, of which the first tranche is $200,000 and will be invested in RxMM’s subsidiary RxMM Healthcare. The Note may be converted at Redfund’s discretion at any time during the term and the Company has a right of first refusal to provide financing to RxMM upon the same business terms as are being offered to RxMM by any other funders. RxMM afforded Redfund stock warrants of its common stock equivalent to twenty percent (20%) of the amount of the Note based upon their current valuation. Security for the loan will be as per the terms of the convertible secured promissory note on RxMM’s FDA approved, globally patented NeuroNasal medical delivery device, which forms an integral part of the Alzheimers Defense product system.
Redfund CEO Meris Kott stated:
“For anyone who has watched a relative’s or friends’ memory disappear before them it is heartbreaking. If Alzheimer Defense helps prevent or slow down the process of memory loss it is a miracle. Redfund is excited to finance the building this revolutionary brand by RxMM and looks forward to supporting RxMM’s other subsidiaries in the near future with additional funding.”
FULL DISCLOSURE: Redfund Capital Corp. is a paid client of Stockhouse Publishing.